Summary - Researchers from National Jewish Health have demonstrated in vivo in a murine model of asthma that administration of IL-12 is effective at substantially improving airway hyperresponsiveness.
Potential Applications - Therapy for respiratory diseases such as asthma
Advantages of Invention
IL-12 is a natural substance therefore decreasing the possibility of toxic side effects
IL-12 could be aerosolized
State of Development - Treatment of a murine model of asthma with IL-12 decreases airway hyperresponsiveness by 80%.
Further R&D Required - In vivo study in other animal models
Patent - US patent # 5,674,483
Inventors - Charles Irvin, PhD and Yuan-Po Tu, MD, DVM
Publication - Kodama et al. Clin Exp. Immunol. 2003 Feb 131(2):199-205
Licensing Status - This technology is available for licensing
For Further Information, Contact: Emmanuel Hilaire, PhD Director Technology Transfer Office National Jewish Health 1400 Jackson Street, Room M206b Denver, CO 80206 Voice: (303) 398-1262 Fax: (303) 270-2352 HilaireE@njhealth.org